Interní Med. 2008; 10(11): 498-501
Novelties in antiretroviral therapy of HIV/AIDS infection
- AIDS centrum FN Na Bulovce, III. klinika infekčních a tropických nemocí 1. LF UK, Praha
HIV infection remains an incurable disease because of the impossibility to eradicate the HIV from the organism. However, the combination antiretroviral therapy (cART) is able to efficiently limit HIV replication and slow down progression of immunodeficienci and thus prolog and improve the quality of HIV+ patients‘ lives. In HIV+ pregnant women, the antiretroviral therapy substantially reduces the risk of vertical transmission of infection. The development of new antiretroviral drugs is breathtaking and the speed with which the US Food and Drug Administration approves new drugs for clinical use is unprecedented. The development continues, extending not only the existing antiretroviral drug families but also yelding new drug families such as entry inhibitors, integrase and maturation inhibitors that proved highly effective in multidrug resistant patiens. Optimal treatment benefits require strict adherence to antiretroviral therapy. Despide the impressive therapeutic advances, we still are not able to eliminate HIV from the body.
Keywords: Key words: HIV infection, nucleoside and non-nucleoside reverse transcriptase inhibitors, protease inhibitors, entry and fusion inhibitors, integrase and maturation inhibitors, adherence.
Published: January 1, 2009 Show citation
References
- Clinical Protocols for the WHO European region: HIV/AIDS treatment and Care. 2007.
- Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-1180.
Go to original source... 
Go to PubMed... - Croxtall JD, Lyseng-Williamson KA, Perry CM. Raltegravir. Drugs 2008; 68(1): 131-138. Go to original source... Go to PubMed...
- Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. May 6, 2006. Available at http://aidsinfo.nih.gov/guidelines, Accessed June 22, 2006.
- Eron JJ. Novel Antiretroviral Agents. In: HIV/AIDS Annual Update 2008 edited by Seeskin E.P. et al. Publisher by Clinical Care Options HIV 2008.
- Kuritzkes DR. Progress of entry inhibitors: Where are we now and where are we going. 26-45. In HIV/AIDS Annual update 2006 edited by Phair JP, Poppa A, King E. Published by Clinical Care Options HIV 2006.
- Mary-Krause M, Cotte L, Simon A et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486. Go to original source... Go to PubMed...
- McDermott AY, Terrin N, Wanke C, et al. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIVinfected adults: a longitudinal study. Clin Infect Dis 2005; 41: 1662-1670. Go to original source... Go to PubMed...
- Sedláček D, Stehlík P, Stožický F. Příspěvek ke kontrole adherence léčby antiretrovirovými přípravky. Klin Mikrobiol Inf. Lék 2001; 7(3): 80-82.
- Sedláček D, Staňková M, Machala L. et al. Komplexní postup antiretrovirové léčby osob infikovaných virem lidské imunodeficience (HIV) v České republice. Klin Mikrobiol Inf Lék 2007; 13(1): 28-34.
- Staňková M, Skokanová V. Problematika HIV/AIDS - ohlédnutí a perspektivy. Klin Mikrobiol Inf Lék 2004; 10: 56-60.
- Staňková M. Změna klinického obrazu HIV infekce při současných možnostech HAART. Trendy v medicíně 2001; 3(2): 1720.
- Staňková M, Skokanová V. Historie a perspektivy antiretrovirové terapie infekce HIV/AIDS. Remedia 2007; 17(2): 175-180.